TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34979928

Group type: EXPERIMENTAL
Intervention: Prolonged sigh breath lung recruitment maneuver (LRM)
Number of subjects: 18
Study: 34979932

Group type: EXPERIMENTAL
Intervention: Qualitative ultrasound assessment of gastric content
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Quantitative ultrasound assessment of gastric volume
Number of subjects: 47
Study: 34979970

Group type: EXPERIMENTAL
Intervention: PDI drugs (e.g., Zolpidem, Zopiclone, Bromazepam, Tramadol, Pregabalin)
Number of subjects: 1783

Group type: EXPERIMENTAL
Intervention: PDI drugs
Number of subjects: 1783
Study: 34979983

Group type: EXPERIMENTAL
Intervention: Bone biopsy to assess bone histomorphometry
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Fluoride activity measurement in lumbar spine
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: PTH measurement
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Erosion surfaces measurement
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Overall calcification score
Number of subjects: 32
Study: 34980020

Group type: EXPERIMENTAL
Intervention: Experimental arms in each cohort
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 6
Study: 34980038

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with three cycles of carboplatin and paclitaxel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single-modality arm (minimally-invasive surgery or radiation alone to 50 Gy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intermediate de-escalation arm (chemoradiation to 50 Gy with cisplatin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regular dose arm (chemoradiation to 70 Gy with concurrent cisplatin)
Number of subjects: 0
Study: 34980055

Group type: EXPERIMENTAL
Intervention: Dorsal approach plantar plate repair using standard operative instruments
Number of subjects: 10
Study: 34980176

Group type: EXPERIMENTAL
Intervention: Administration of an adenovirus targeting SNHG15
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SNHG15
Number of subjects: 0
Study: 34980185

Group type: EXPERIMENTAL
Intervention: Cardiovascular magnetic resonance (CMR) using anatomically correct contouring method
Number of subjects: 3206

Group type: EXPERIMENTAL
Intervention: Cardiovascular magnetic resonance (CMR)
Number of subjects: 3206
Study: 34980199

Group type: EXPERIMENTAL
Intervention: 4D flow CMR parameters in rTOF patients
Number of subjects: 63

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 63
Study: 34980208

Group type: EXPERIMENTAL
Intervention: Personalized daily text messaging (SMS/MMS), posts on social media platforms, and online groups
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: Personalized daily text messaging (SMS/MMS), posts on social media platforms, online groups, and brief technology-mediated health coaching
Number of subjects: 642

Group type: COMPARATOR
Intervention: Wearable activity tracker, connected scale, and corresponding app alone
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: Both SMART 2.0 intervention groups
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: Group receiving health coaching
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: Secondary outcomes
Number of subjects: 642
Study: 34980220

Group type: EXPERIMENTAL
Intervention: Intramuscular progesterone 40 mg per day from D3 to 8 weeks of gestation if clinical pregnancy is achieved.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low serum progesterone group (control).
Number of subjects: 0
Study: 34980224

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (50 mg intravenous bolus every 6 hours) and fludrocortisone (50 μg once a day enterally) for 7 days or until discharge from the ICU
Number of subjects: 380

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 380
Study: 34980502

Group type: EXPERIMENTAL
Intervention: SSTR2-targeted peptide-radionuclide receptor therapy (PRRT)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Prophylactic neck irradiation
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Dural infiltration at presentation
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Kadish-Morita staging and Dulguerov T-stage
Number of subjects: 404
Study: 34980541

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus trastuzumab (arms B&C)
Number of subjects: 1282

Group type: COMPARATOR
Intervention: Chemotherapy (arm A)
Number of subjects: 1282
Study: 34980577

Group type: EXPERIMENTAL
Intervention: Azacitidine and Nivolumab
Number of subjects: 236

Group type: COMPARATOR
Intervention: AML with diploid karyotype
Number of subjects: 236

Group type: COMPARATOR
Intervention: Next Generation Sequencing
Number of subjects: 236
Study: 34980597

Group type: EXPERIMENTAL
Intervention: Nivolumab 240 mg every 2 weeks + cabozantinib 40 mg every day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nivolumab 480 mg every 4 weeks + cabozantinib 40 mg every day
Number of subjects: 0
Study: 34980611

Group type: EXPERIMENTAL
Intervention: Digital Care Path for Living Kidney Donor Candidates
Number of subjects: 122
Study: 34980610

Group type: EXPERIMENTAL
Intervention: Adaptive deep brain stimulation (aDBS)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Conventional deep brain stimulation (cDBS)
Number of subjects: 15
Study: 34980614

Group type: EXPERIMENTAL
Intervention: Fertility Health Screening group (FHS)
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Fertility Awareness Tools (FAT)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 1200
Study: 34980633

Group type: EXPERIMENTAL
Intervention: Point-of-care C reactive protein (POC CRP) testing, prescription guidance, and safety-netting advice.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 34980909

Group type: EXPERIMENTAL
Intervention: Lentiviral globin gene therapy with reduced-intensity conditioning
Number of subjects: 4
Study: 34981068

Group type: EXPERIMENTAL
Intervention: Convalescent plasma
Number of subjects: 1181

Group type: COMPARATOR
Intervention: Placebo control plasma
Number of subjects: 1181
Study: 34981077

Group type: EXPERIMENTAL
Intervention: Bamlanivimab 7000 mg
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Bamlanivimab 700 mg
Number of subjects: 317

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Bamlanivimab 7000 mg and 700 mg
Number of subjects: 317
Study: 34981142

Group type: EXPERIMENTAL
Intervention: CC-90002 (anti-CD47 monoclonal antibody) administered in escalating doses of 0.1-4.0 mg/kg
Number of subjects: 28
Study: 34981144

Group type: EXPERIMENTAL
Intervention: Deferiprone (DFP), single 1500 mg dose
Number of subjects: 8
Study: 34981300

Group type: EXPERIMENTAL
Intervention: Hypofractionated stereotactic radiotherapy (HSRT) with doses of either 27.5 or 30 Gy
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: T1c sequence imaging
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: T2f sequence imaging
Number of subjects: 15
Study: 34981464

Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT) for 16 sessions
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: High frequency-rapid response in binge eating
Number of subjects: 56
Study: 34981890

Group type: EXPERIMENTAL
Intervention: Electrical stimulation to activate recurrent collaterals resulting in Hoffmann reflex depression in ALS patients
Number of subjects: 38

Group type: COMPARATOR
Intervention: Electrical stimulation to activate recurrent collaterals resulting in Hoffmann reflex depression in controls
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Enhanced recurrent inhibition observed in ALS patients within the first year after symptom onset
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Normal or reduced inhibitions in ALS patients with motor weakness first in lower limbs
Number of subjects: 38
Study: 34982018

Group type: EXPERIMENTAL
Intervention: Augmented Reality (AR) Leaflet
Number of subjects: 12

Group type: COMPARATOR
Intervention: Traditional Leaflet
Number of subjects: 12
Study: 34982055

Group type: EXPERIMENTAL
Intervention: Low heart rate (<65 bpm)
Number of subjects: 1760

Group type: EXPERIMENTAL
Intervention: High heart rate (≥86 bpm)
Number of subjects: 1760

Group type: EXPERIMENTAL
Intervention: High heart rate (≥86 bpm) among patients with LVEF ≥50%
Number of subjects: 1760

Group type: EXPERIMENTAL
Intervention: Low heart rate (<65 bpm) among patients with LVEF <50%
Number of subjects: 1760
Study: 34982337

Group type: EXPERIMENTAL
Intervention: Paternal perception of child weight status
Number of subjects: 591

Group type: EXPERIMENTAL
Intervention: Maternal perception of child weight status
Number of subjects: 591
Study: 34982397

Group type: EXPERIMENTAL
Intervention: Ad-DiaRem score for SG
Number of subjects: 109

Group type: COMPARATOR
Intervention: Ad-DiaRem score for RYGB
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: ABCD score for SG
Number of subjects: 109

Group type: COMPARATOR
Intervention: ABCD score for RYGB
Number of subjects: 109

Group type: COMPARATOR
Intervention: Diabetes remission in RYGB group
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Diabetes duration and glycated haemoglobin
Number of subjects: 109
Study: 34982399

Group type: EXPERIMENTAL
Intervention: Contemporary management strategies for acute PE
Number of subjects: 4000
Study: 34983109

Group type: EXPERIMENTAL
Intervention: Mobile management
Number of subjects: 923

Group type: COMPARATOR
Intervention: Traditional management
Number of subjects: 923
Study: 34983125

Group type: EXPERIMENTAL
Intervention: Male urinary incontinence (UI)
Number of subjects: 4076
Study: 34983237

Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 224

Group type: COMPARATOR
Intervention: Women
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Total plaque volume
Number of subjects: 224
Study: 34983430

Group type: EXPERIMENTAL
Intervention: Monocyte Distribution Width (MDW) with cutoff of 20
Number of subjects: 402

Group type: COMPARATOR
Intervention: Procalcitonin (PCT) with cutoff of 0.5 ng/mL
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: MDW combined with WBC count
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: MDW for predicting sepsis-3 with cutoff of 20
Number of subjects: 402

Group type: COMPARATOR
Intervention: PCT for predicting sepsis-3 with cutoff of 0.5 ng/mL
Number of subjects: 402
Study: 34983488

Group type: EXPERIMENTAL
Intervention: Digital Care Program (DCP) for acute MSK pain
Number of subjects: 343
Study: 34983600

Group type: EXPERIMENTAL
Intervention: Early, biomarker-guided steroid dosing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34983611

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 pneumonia group
Number of subjects: 1047

Group type: COMPARATOR
Intervention: Influenza pneumonia group
Number of subjects: 1047
Study: 34983621

Group type: EXPERIMENTAL
Intervention: PERC (Prostate Cancer Education & Resources for Couples)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care plus the National Cancer Institute prostate cancer website (Control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PERC
Number of subjects: 0
Study: 34983665

Group type: EXPERIMENTAL
Intervention: Checklist-based box system intervention
Number of subjects: 1062

Group type: COMPARATOR
Intervention: Government-led maternal health program (Control)
Number of subjects: 1062
Study: 34983671

Group type: EXPERIMENTAL
Intervention: First Phase Insulin Response (FPIR) in IvGTT
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Presence of ZnT8 autoantibodies
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Fasting glucose and HbA1c
Number of subjects: 57
Study: 34983749

Group type: EXPERIMENTAL
Intervention: Weighted fibre blankets (active)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Fibre blankets without weight (control)
Number of subjects: 100
Study: 34983751

Group type: EXPERIMENTAL
Intervention: Protein supplementation of ≥1.5 g/kg/day in addition to standard nutrition for 7 days or until PICU discharge.
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard nutrition alone for 7 days or until PICU discharge.
Number of subjects: 70
Study: 34983756

Group type: EXPERIMENTAL
Intervention: AI algorithm (CNN) used for lesion assessment during the postintervention period.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AI-assisted decision by the registrar.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preintervention period (no AI assessment) vs Postintervention period (AI assessment).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AI algorithm's sensitivity, specificity, and agreement with histopathology or treating consultant dermatologists' classification.
Number of subjects: 0
Study: 34983758

Group type: EXPERIMENTAL
Intervention: Cessation programme with 3-monthly visits
Number of subjects: 182

Group type: COMPARATOR
Intervention: Control group with annual visits
Number of subjects: 182
Study: 34983760

Group type: EXPERIMENTAL
Intervention: YC-PEM e-PRO measure and decision support tool
Number of subjects: 223

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 223
Study: 34983769

Group type: EXPERIMENTAL
Intervention: Higher PHQ-9 scores
Number of subjects: 2365

Group type: COMPARATOR
Intervention: Lower PHQ-9 scores
Number of subjects: 2365
Study: 34984540

Group type: EXPERIMENTAL
Intervention: Sugemalimab (1200 mg fixed dose once every 3 weeks)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Sugemalimab (monotherapy)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Sugemalimab (in combination with SOC chemotherapy)
Number of subjects: 207
Study: 34985583

Group type: EXPERIMENTAL
Intervention: Childhood adversity (CA)
Number of subjects: 1084

Group type: EXPERIMENTAL
Intervention: Adulthood adversity (AA)
Number of subjects: 1084

Group type: EXPERIMENTAL
Intervention: Both childhood and adulthood adversity (CA and AA)
Number of subjects: 1084

Group type: COMPARATOR
Intervention: Neither CA nor AA alone
Number of subjects: 1084
Study: 34985974

Group type: EXPERIMENTAL
Intervention: Nanobody-functionalized cellulose
Number of subjects: 0
Study: 34986183

Group type: EXPERIMENTAL
Intervention: dayzz smartphone app
Number of subjects: 0

Group type: COMPARATOR
Intervention: waitlist control (no immediate access to the dayzz app)
Number of subjects: 0
Study: 34986271

Group type: COMPARATOR
Intervention: Low-added sugar intake
Number of subjects: 1110
Study: 34986409

Group type: EXPERIMENTAL
Intervention: Deep endometriosis surgery
Number of subjects: 32
Study: 34987618

Group type: EXPERIMENTAL
Intervention: Dendritic cell vaccines (DCV) plus neoadjuvant chemotherapy (NAC)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy (NAC) alone
Number of subjects: 39
Study: 34987619

Group type: EXPERIMENTAL
Intervention: Clinical and imaging examinations for axial involvement in PsA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imaging evaluations including radiography and magnetic resonance imaging of sacroiliac joints and spine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Central clinical committee evaluation
Number of subjects: 0
Study: 34987638

Group type: EXPERIMENTAL
Intervention: MMP-degradable and conductive hydrogel
Number of subjects: 0
Study: 34988092

Group type: EXPERIMENTAL
Intervention: CytoSorb Therapy
Number of subjects: 0
Study: 34988132

Group type: EXPERIMENTAL
Intervention: Oral Water
Number of subjects: 0
Study: 34988154

Group type: EXPERIMENTAL
Intervention: Transbronchial cryobiopsy (TBCB)
Number of subjects: 373
Study: 34988234

Group type: EXPERIMENTAL
Intervention: Bipolar radiofrequency microtenotomy (RFM)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Physical therapy (PT)
Number of subjects: 38
Study: 34988237

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 108

Group type: COMPARATOR
Intervention: Men
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Both sexes
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Intercondylar notch width and lateral tibial slope
Number of subjects: 108
Study: 34988299

Group type: EXPERIMENTAL
Intervention: Radiotherapy for aggressive brain tumor (Group 1)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: No radiotherapy for low-grade brain tumor (Group 2)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (Group 3)
Number of subjects: 90
Study: 34988480

Group type: EXPERIMENTAL
Intervention: Chemoradiation treatment for esophageal cancer
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Pre-existing atrial fibrillation and a dilated left atrium
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Left ventricular (LV) systolic dysfunction
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Systematic cardiac evaluation prior to chemoradiation
Number of subjects: 55
Study: 34988735

Group type: EXPERIMENTAL
Intervention: NBI-assisted diagnosis by endoscopist
Number of subjects: 451
Study: 34988780

Group type: EXPERIMENTAL
Intervention: DiffCORE MR formulations (240 mg) administered in fasted and fed states
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DiffCORE MR-16 h formulation (120-960 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immediate-release formulation
Number of subjects: 0
Study: 34988917

Group type: EXPERIMENTAL
Intervention: Treatment intensification (addition of new insulin, increase in insulin dosage, increase in insulin injection frequency, addition of non-insulin antihyperglycemic agents)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Insulin intensification (increase in insulin dose, addition of new insulin, increase in insulin injection frequency)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Increase in insulin dose
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Addition of new insulin
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Increase in insulin injection frequency
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: HbA1c change from baseline
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Overall HbA1c levels
Number of subjects: 116
Study: 34989180

Group type: EXPERIMENTAL
Intervention: Felcisetrag 0.2-mg intravenous dose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Itraconazole 200-mg oral doses
Number of subjects: 0
Study: 34989677

Group type: EXPERIMENTAL
Intervention: Calm app (meditation intervention)
Number of subjects: 83

Group type: COMPARATOR
Intervention: POD (educational podcasts; control)
Number of subjects: 83
Study: 34989701

Group type: EXPERIMENTAL
Intervention: Plasma transfusions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Platelet transfusions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Laboratory tests and physiologic triggers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Product attributes
Number of subjects: 0
Study: 34989842

Group type: EXPERIMENTAL
Intervention: Radiologic scores for guiding individualized induction chemotherapy
Number of subjects: 542
Study: 34989876

Group type: EXPERIMENTAL
Intervention: Cranial cervical parameters (McGregor slope, occipito-C2 angle, McGregor-C2 lordosis, C1-C2 lordosis)
Number of subjects: 2599

Group type: EXPERIMENTAL
Intervention: Cranial cervical parameters in low PI
Number of subjects: 2599

Group type: EXPERIMENTAL
Intervention: Caudal cervical parameters (C2-C7 lordosis, C7-slope, T1-slope)
Number of subjects: 2599

Group type: EXPERIMENTAL
Intervention: Caudal arch lordosis after 35 years
Number of subjects: 2599

Group type: EXPERIMENTAL
Intervention: Cervical alignment parameters
Number of subjects: 2599

Group type: EXPERIMENTAL
Intervention: Caudal cervical arch
Number of subjects: 2599

Group type: EXPERIMENTAL
Intervention: Correlations between cervical parameters and thoracic kyphosis
Number of subjects: 2599
Study: 34990002

Group type: EXPERIMENTAL
Intervention: Baricitinib 2-mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34990207

Group type: EXPERIMENTAL
Intervention: Serial 7 mental arithmetic stress test
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Cold pressor test
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Electrical stimulation
Number of subjects: 23

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 23
Study: 34990408

Group type: EXPERIMENTAL
Intervention: Low-dose aerosol (LD) AdHu5Ag85A
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: High-dose aerosol (HD) AdHu5Ag85A
Number of subjects: 31

Group type: COMPARATOR
Intervention: Intramuscular (i.m.) injection of AdHu5Ag85A
Number of subjects: 31
Study: 34990411

Group type: EXPERIMENTAL
Intervention: Individuals with sickle cell disease (SCD)
Number of subjects: 74190

Group type: EXPERIMENTAL
Intervention: Hydroxyurea use in individuals with SCD
Number of subjects: 74190

Group type: COMPARATOR
Intervention: Controls (individuals without SCD)
Number of subjects: 74190
Study: 34990764

Group type: EXPERIMENTAL
Intervention: Vasopressin and glucocorticoids
Number of subjects: 869
Study: 34990778

Group type: EXPERIMENTAL
Intervention: Proton radiation therapy (PRT) at a dose of 54 Gy relative biological effectiveness
Number of subjects: 94
Study: 34990810

Group type: EXPERIMENTAL
Intervention: Self-amplifying mRNA (SAM) vaccine delivered by lipid nanoparticles (LNPs); two doses administered.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-amplifying mRNA (SAM) vaccine; two doses administered.
Number of subjects: 0
Study: 34991141

Group type: EXPERIMENTAL
Intervention: BIC/FTC/TAF coformulated as a single daily pill for 28 days
Number of subjects: 52

Group type: COMPARATOR
Intervention: Historical PEP regimens (not specified)
Number of subjects: 52
Study: 34991479

Group type: EXPERIMENTAL
Intervention: Frailty assessment using the electronic Frailty Index (eFI)
Number of subjects: 2177656

Group type: EXPERIMENTAL
Intervention: Analysis of health service use and care needs
Number of subjects: 2177656
Study: 34991511

Group type: EXPERIMENTAL
Intervention: Emotion regulation-enhanced group treatment
Number of subjects: 21
Study: 34991520

Group type: EXPERIMENTAL
Intervention: OncoSNIPE® study intervention
Number of subjects: 600
Study: 34991653

Group type: EXPERIMENTAL
Intervention: Galectin-3 plasma level measurement at ICU admission
Number of subjects: 2076
Study: 34991660

Group type: EXPERIMENTAL
Intervention: Unmet medication needs
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Higher proportion of unmet medication needs
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no unmet medication needs)
Number of subjects: 200
Study: 34991679

Group type: EXPERIMENTAL
Intervention: Ponatinib
Number of subjects: 449
Study: 34991688

Group type: EXPERIMENTAL
Intervention: Dubbing language cinema-based therapy
Number of subjects: 54